A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk's underperformance in recent weeks is attributed to a patent challenge by Viatris over its weight-loss therapy, Wegovy. Read more here.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

If Viatris could sell generic versions of Wegovy and Ozempic, it'd be a major driver of new top-line growth. Sales of Ozempic brought in more than $3 billion for Novo Nordisk in the most recent ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Novo Nordisk, the maker of Wegovy, announced exclusively on "Good Morning America" Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...

As of May 22, manufacturers are no longer allowed to distribute the compounded versions of semaglutide, which Novo Nordisk sells under the brand Wegovy for weight loss and Ozempic for diabetes.

Viatris is trying to launch generic versions of Novo Nordisk's Ozempic and Wegovy. It should experience an uptick in growth soon, and the stock's valuation is cheap. It's important to keep ...

Read here to know Viatris ... For now, NVO's Wegovy/ Ozempic and Eli Lilly's Mounjaro have been heralded as the next golden goose in the biotech/ pharmaceutical sector, ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Consumers looking to start the popular weight loss drug Wegovy but lacking insurance coverage will soon have a new option. Novo Nordisk, the maker of Wegovy, announced exclusively on "Good Morning ...